Published in Breast Cancer Res on October 06, 2005
Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev (2008) 1.80
Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer (2010) 1.58
The internally truncated LRP5 receptor presents a therapeutic target in breast cancer. PLoS One (2009) 1.12
The impact of vitamin D in breast cancer: genomics, pathways, metabolism. Front Physiol (2014) 1.06
Vitamin D and the mammary gland: a review on its role in normal development and breast cancer. Breast Cancer Res (2012) 1.02
25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. Breast Cancer Res Treat (2012) 0.94
Ergocalciferol decreases erythropoietin resistance in children with chronic kidney disease stage 5. Pediatr Nephrol (2013) 0.90
Vitamin D3 deficiency differentially affects functional and disease outcomes in the G93A mouse model of amyotrophic lateral sclerosis. PLoS One (2011) 0.85
Altered expression of key players in vitamin D metabolism and signaling in malignant and benign thyroid tumors. J Histochem Cytochem (2012) 0.85
25-Hydroxyvitamin D3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture. Breast Cancer Res Treat (2008) 0.84
Can a single model explain both breast cancer and prostate cancer? Theor Biol Med Model (2007) 0.83
Vitamin D metabolism in human bone marrow stromal (mesenchymal stem) cells. Metabolism (2013) 0.83
Loss of vitamin D receptor signaling from the mammary epithelium or adipose tissue alters pubertal glandular development. Am J Physiol Endocrinol Metab (2014) 0.80
Dietary vitamin D exposure prevents obesity-induced increase in endometrial cancer in Pten+/- mice. Cancer Prev Res (Phila) (2010) 0.78
Genetic Polymorphisms in Vitamin D Metabolism and Signaling Genes and Risk of Breast Cancer: A Nested Case-Control Study. PLoS One (2015) 0.75
Function of the vitamin D endocrine system in mammary gland and breast cancer. Mol Cell Endocrinol (2017) 0.75
Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab (2001) 4.47
Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet (2000) 4.13
Current understanding of the molecular actions of vitamin D. Physiol Rev (1998) 4.05
Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene (2002) 2.02
Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev (1998) 1.69
25-Hydroxyvitamin D(3)-1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids (2001) 1.61
25-hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. Lancet (2001) 1.61
Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol Endocrinol (1997) 1.57
Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer (2002) 1.48
Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in the human kidney. J Am Soc Nephrol (1999) 1.47
Glyceraldehyde-3-phosphate dehydrogenase gene expression in human breast cancer. Eur J Cancer (2000) 1.42
Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol (2001) 1.40
Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res (2001) 1.36
Human bone cells in culture metabolize 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3. J Biol Chem (1981) 1.33
Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol (2002) 1.30
1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death. Cancer Res (2000) 1.26
Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J Biol Chem (2000) 1.26
25-hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab (2002) 1.24
A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer (1998) 1.19
25-hydroxy-vitamin d metabolism in human colon cancer cells during tumor progression. Biochem Biophys Res Commun (2001) 1.15
Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology (1999) 1.11
EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro. Br J Pharmacol (1998) 1.08
Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res (1991) 1.06
Modulation of cell cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells. Oncogene (1997) 1.03
25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol (2002) 1.01
Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo. Breast Cancer Res Treat (1999) 0.98
Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. J Urol (2002) 0.95
Immunocytochemical detection of 1,25-dihydroxyvitamin D3 receptor in breast cancer. Cancer Res (1987) 0.94
The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clin Cancer Res (2000) 0.92
Vitamin D metabolism in human colon adenocarcinoma-derived Caco-2 cells: expression of 25-hydroxyvitamin D3-1alpha-hydroxylase activity and regulation of side-chain metabolism. J Steroid Biochem Mol Biol (1997) 0.92
Inhibitors of vitamin D hydroxylases: structure-activity relationships. J Cell Biochem (2003) 0.91
Functional characterization of a 1,25-dihydroxyvitamin D3 receptor binding site found in the rat atrial natriuretic factor promoter. Biochem Biophys Res Commun (1996) 0.91
Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. Cancer Res (1994) 0.90
Constitutive expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in a transformed human proximal tubule cell line: evidence for direct regulation of vitamin D metabolism by calcium. Endocrinology (1999) 0.88
Expression of 25-hydroxyvitamin D-1-alpha-hydroxylase mRNA in individuals with colorectal cancer. Lancet (2002) 0.88
Role of 24-hydroxylase in vitamin D3 growth response of OVCAR-3 ovarian cancer cells. Int J Cancer (2004) 0.86
Vitamin D analogs as therapeutic agents: a clinical study update. Curr Opin Investig Drugs (2004) 0.86
The vitamin D3 analog EB 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells. Breast Cancer Res Treat (2000) 0.84
Metabolism of the vitamin D analog EB1089 by cultured human cells: redirection of hydroxylation site to distal carbons of the side-chain. Biochem Pharmacol (1997) 0.84
Interactions of vitamin D analogue CB1093, TNFalpha and ceramide on breast cancer cell apoptosis. Mol Cell Endocrinol (2001) 0.82
Increased 25-hydroxyvitamin D3 1alpha-hydroxylase and reduced 25-hydroxyvitamin D3 24-hydroxylase expression in parathyroid tumors--new prospects for treatment of hyperparathyroidism with vitamin d. J Clin Endocrinol Metab (2002) 0.82
Targeted disruption of the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in ras-transformed keratinocytes demonstrates that locally produced 1alpha,25-dihydroxyvitamin D3 suppresses growth and induces differentiation in an autocrine fashion. Mol Cancer Res (2002) 0.81
Novel vitamin D3 analog (CB1093) when combined with paclitaxel and cisplatin inhibit growth of MCF-7 human breast cancer cells in vivo. Int J Oncol (1998) 0.78
Vitamin D3 polyunsaturated side-chain analogues (EB1089, GS1590) and the 20-epi-vitamin D3 analogue CB1393 suppress parathyroid hormone secretion and mRNA level in bovine parathyroid cells. J Steroid Biochem Mol Biol (2004) 0.78
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res (2006) 8.08
K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science (2011) 5.40
FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res (2007) 3.79
Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation (2009) 2.85
Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol (2007) 2.31
Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet (2013) 2.09
Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. N Engl J Med (2008) 2.01
SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol (2006) 1.76
Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int (2010) 1.70
Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing. J Clin Endocrinol Metab (2013) 1.69
Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am J Clin Nutr (2010) 1.64
Plasma 25-hydroxyvitamin D levels and fracture risk in a community-based cohort of elderly men in Sweden. J Clin Endocrinol Metab (2010) 1.43
Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg (2002) 1.35
Imaging for primary hyperparathyroidism--an evidence-based analysis. Langenbecks Arch Surg (2009) 1.30
Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. PLoS One (2012) 1.30
EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol (2007) 1.28
Management of midgut carcinoids. J Surg Oncol (2005) 1.28
25-hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab (2002) 1.24
Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab (2007) 1.21
Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol (2010) 1.15
Surgical treatment of Graves' disease: evidence-based approach. World J Surg (2008) 1.15
Differential regulation of survivin expression and apoptosis by vitamin D3 compounds in two isogenic MCF-7 breast cancer cell sublines. Oncogene (2005) 1.12
The internally truncated LRP5 receptor presents a therapeutic target in breast cancer. PLoS One (2009) 1.12
[11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab (2006) 1.11
MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr Relat Cancer (2010) 1.11
Correlation between plasma calcium, parathyroid hormone (PTH) and the metabolic syndrome (MetS) in a community-based cohort of men and women. Clin Endocrinol (Oxf) (2009) 1.10
EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. Ann Surg Oncol (2008) 1.08
Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immunol (2006) 1.08
CCAAT/enhancer-binding protein delta: a molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells. Cancer Res (2005) 1.08
Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. BMC Med (2006) 1.08
Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg (2012) 1.07
Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer. Carcinogenesis (2003) 1.07
Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol (2014) 1.05
Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg (2008) 1.05
Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur J Heart Fail (2010) 1.05
The combination of a potent vitamin D3 analog, EB 1089, with ionizing radiation reduces tumor growth and induces apoptosis of MCF-7 breast tumor xenografts in nude mice. Clin Cancer Res (2003) 1.04
An LRP5 receptor with internal deletion in hyperparathyroid tumors with implications for deregulated WNT/beta-catenin signaling. PLoS Med (2007) 1.03
Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors. Genes Chromosomes Cancer (2011) 1.03
Molecular genetics of parathyroid disease. World J Surg (2009) 1.01
4D parathyroid CT as the initial localization study for patients with de novo primary hyperparathyroidism. Ann Surg Oncol (2010) 1.00
Pancreatic tumours as part of the MEN-1 syndrome. Best Pract Res Clin Gastroenterol (2005) 1.00
Anticancer agent CHS 828 suppresses nuclear factor-kappa B activity in cancer cells through downregulation of IKK activity. Int J Cancer (2004) 0.99
Vanishing bile duct-like syndrome in a patient with Hodgkin lymphoma - pathological development and restitution. Acta Oncol (2014) 0.98
Reduced p18INK4c, p21CIP1/WAF1 and p27KIP1 mRNA levels in tumours of primary and secondary hyperparathyroidism. Clin Endocrinol (Oxf) (2004) 0.98
High success rate of parathyroid reoperation may be achieved with improved localization diagnosis. World J Surg (2008) 0.97
Risk of second primary malignancies and causes of death in patients with adenocarcinoma and carcinoid of the small intestine. Eur J Cancer (2008) 0.97
Cyclin-dependent kinase 4 (CDK4) expression in pancreatic endocrine tumors. Neuroendocrinology (2007) 0.96
Association of parathyroid adenoma and pregnancy with preeclampsia. J Clin Endocrinol Metab (2009) 0.96
Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. Acta Oncol (2007) 0.95
Role of follistatin in promoting adipogenesis in women. J Clin Endocrinol Metab (2009) 0.95
Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen. Eur J Cancer (2006) 0.95
Midgut carcinoid tumours: surgical treatment and prognosis. Best Pract Res Clin Gastroenterol (2005) 0.95
Positional statement of the European Society of Endocrine Surgeons (ESES) on modern techniques in pHPT surgery. Langenbecks Arch Surg (2009) 0.95
Accumulation of nonphosphorylated beta-catenin and c-myc in primary and uremic secondary hyperparathyroid tumors. J Clin Endocrinol Metab (2006) 0.94
Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. Langenbecks Arch Surg (2002) 0.94
Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg (2002) 0.94
Integrative epigenomic and genomic analysis of malignant pheochromocytoma. Exp Mol Med (2010) 0.93
Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors. Genes Chromosomes Cancer (2012) 0.93
Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability. PLoS One (2010) 0.93
Adsorption and solar light decomposition of acetone on anatase TiO2 and niobium doped TiO2 thin films. J Phys Chem B (2006) 0.93
Vitamin D3 analogs stimulate hair growth in nude mice. Endocrinology (2002) 0.92
Activated Neu/ErbB-2 induces expression of the vascular endothelial growth factor gene by functional activation of the transcription factor Sp 1. Angiogenesis (2004) 0.92
Transfection of the multiple endocrine neoplasia type 1 gene to a human endocrine pancreatic tumor cell line inhibits cell growth and affects expression of JunD, delta-like protein 1/preadipocyte factor-1, proliferating cell nuclear antigen, and QM/Jif-1. J Clin Endocrinol Metab (2004) 0.92
Stenting of the superior mesenteric vein in midgut carcinoid disease with large mesenteric masses. World J Surg (2010) 0.91